Pilot study of Vyvanse (lisdexamfetamine dimesylate) in adolescents (ages 11-15) with ADHD [attention deficit hyperactivity disorder] and an older sibling with ADHD and substance dependence.

Trial Profile

Pilot study of Vyvanse (lisdexamfetamine dimesylate) in adolescents (ages 11-15) with ADHD [attention deficit hyperactivity disorder] and an older sibling with ADHD and substance dependence.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder; Substance-related disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Nov 2011 Primary endpoint identified as 'Number of Participants With at Least 70% Reduction in ADHD Symptoms as Measured by Change in ADHD Rating Scale From First to Last Visit' as reported by ClinicalTrials.gov.
    • 28 Nov 2011 Actual patient number changed from 30 to 8 according to ClinicalTrials.gov.
    • 20 Oct 2010 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top